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ABSTRACT
Objectives: In countries with high income, tocolytic therapy
with b-mimetic agents is a cost-effective strategy compared to
placebo. In our study, the cost-effectiveness of two b-mimetic
agents, ritodrine and fenoterol, used in the management of
preterm labor was compared in the setting of a low–middle-
income transitional country, Serbia & Montenegro.
Methods: This case study was conducted at the
Gynecology-Obstetrics Clinic, Clinical Center “Kraguje-
vac,” in Kragujevac, Serbia & Montenegro, between
October 2004 and January 2006. In total, 235 pregnant
patients with threatened preterm labor were enrolled, but 35
were lost to follow-up. Of the remaining 200 patients, 85
were given ritodrine, and 115 fenoterol. The perspective of
Republic Institute for Health Insurance in Serbia was taken
into account. Only direct costs were calculated; primary
outcomes of the study were length of pregnancy (in weeks),
time passed from the onset of uterine contractions to deliv-
ery (in weeks), and score on modiﬁed Flanagan’s quality-of-
life scale for chronic diseases, measured after discharge from
hospital.
Results: Prolongation of pregnancy was signiﬁcantly longer
in the fenoterol group (12.7  8.4 weeks) than in the ritodrine
group (11.6  7.1 weeks). The mean duration of hospitaliza-
tion was shorter in the fenoterol group (11.9  8.8 days) than
in the ritodrine group (14.9  11.3 days). The treatment
with fenoterol was less costly and more cost-effective than
the treatment with ritodrine, but the difference in cost-
effectiveness was not statistically signiﬁcant. The cost of
treatment per gained week of pregnancy prolongation
was 3345.51  7668.04 CSD in the fenoterol group, and
4181.96  12,069.83 CSD in the ritodrine group.
Conclusions: The observed differences in treatment costs
and duration of hospitalization per patient did not translate
into signiﬁcant differences in cost-effectiveness ratios,
because of low costs of hospitalization and human labor in
Serbian health system. Nevertheless, fenoterol treatment still
has a tendency to be more cost-effective, and its lower acqui-
sition cost is an advantage to this treatment option.
Keywords: b-mimetic, cost-effectiveness, preterm labor,
tocolytics.
Introduction
The b-mimetic agents, ritodrine and fenoterol, admin-
istered via intravenous infusion, have proven efﬁcacy
for short-term tocolysis. Either tocolytic can be used as
ﬁrst-line tocolysis in patients without serious cardio-
vascular disease [1–3]. Nevertheless, there are con-
ﬂicting results concerning the effectiveness of oral
b-mimetic agents in the maintenance treatment of
preterm labor. A meta-analysis and two large random-
ized, placebo-controlled trials have showed that oral
maintenance treatment offers no advantage over
placebo during the latency phase or for the recurrence
rate of preterm labor and the rate of preterm delivery
[4]. On the other hand, several smaller, placebo-
controlled studies found that oral maintenance treat-
ment with b-mimetic agents was beneﬁcial [5,6].
Nevertheless, gynecologists in Serbia continue to use
oral tocolytic therapy in their routine daily practice.
In high-income economies, tocolytic therapy with
b-mimetic agents is cost-effective compared to placebo
[7], and with oxytocin receptor antagonist, atosiban
[8]. A tocolysis protocol using a b-mimetic agent as
ﬁrst choice and atosiban as the rescue drug is the most
cost-effective option based on available evidence [9].
The pharmacoeconomics of the b-mimetic agents as
tocolytics in low–middle-income economies has not
been studied. Excluding Greece, all other Balkan coun-
tries (Serbia & Montenegro, Bulgaria, Romania, FYR
Macedonia, Albania, Bosnia and Hercegovina) are
low–middle-income economies (2004 gross national
income per capita from $826 to $3255) [10], with
similar annual health budget per capita (Albania $94,
Bosnia and Hercegovina $130, Bulgaria $145, FYR
Macedonia $124, Serbia & Montenegro $120,
and Romania $128) [11]. Although drug costs in
Balkan countries are similar to costs in developed Euro-
pean countries, the costs of health-care services are
much lower [12]. This creates a different economic
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environment in health care, and could produce differ-
ences in cost-effectiveness or cost-utility of the same
drug between high-income European countries and
low–middle-income Balkan countries.
The aim of our study was to investigate the cost-
effectiveness of two b-mimetic agents, ritodrine and
fenoterol, used for treatment of preterm labor in the
health system of the low–middle-income Serbian
economy.
Material and Methods
Our study was designed as a detailed, in-depth
case study [13] of patients with threatened preterm
labor treated with b-mimetic tocolytics, ritodrine or
fenoterol.
The Perspective and the Time Frame
In Serbia, the Republic Institute for Health Insurance
(RIHI) is the institution that makes contracts with
health facilities and controls prices of services and
drugs. Our study was carried out within this frame-
work. Only services and costs recognized by RIHI
were taken into account when calculating cost-
effectiveness of the study drugs. The observations of
effects and costs were taken in the time period from
emergence of uterine contractions to delivery.
The Patients
The study was conducted on patients of Gynecology-
Obstetrics Clinic, Clinical Center “Kragujevac,” in
Kragujevac, Serbia & Montenegro. All patients of the
Clinic who were pregnant, with premature uterine
contractions and threatened preterm labor during the
period of October 2004 to January 2006 were enrolled
in the study. In total, 235 patients entered the study,
but 35 were lost to follow-up. The investigators did
not interfere with clinical decision of gynecologists to
use tocolytics, or with the choice between ritodrine
and fenoterol. Ritodrine was prescribed to 85 patients
(mean age of the patients 27.2  5.2 years, mean ges-
tational age when uterine contractions commenced
26.6  6.7 weeks), and administered by intravenous
infusion for 3 to 7 days (initially 50 mg/minute,
increased gradually by 50 mg/minute every 10–15
minutes until contractions stop, or maternal heart rate
reaches 140 beats/minute; then maintenance infusion
of 150 mg/minute), followed by oral therapy with sus-
tained release oral formulation of ritodrine, 40 to
80 mg daily. Fenoterol was prescribed to 115 patients
(mean age of the patients 26.8  5.2 years, mean ges-
tational age when uterine contractions commenced
25.4  7.9 weeks), and administered by intravenous
infusion for 3 to 7 days (1–4 mg/min), followed by oral
therapy, 5 mg every 3 to 6 hours. The duration of oral
tocolytic therapy was 10.3  4.5 days in the ritodrine
group, and 9.6  3.8 days in the fenoterol group.
All patients received concomitantly verapamil, 80
to 120 mg daily, orally, and diazepam, 5 mg daily,
orally, throughout the b-mimetic therapy.
The Effects
Primary outcomes of the study were length of preg-
nancy (in weeks), time passed from the onset of uterine
contractions to delivery, that is, prolongation of the
pregnancy (in weeks), and score on modiﬁed Flana-
gan’s quality-of-life scale for chronic diseases [14],
measured after discharge from the hospital.
Secondary outcomes were prolongation of the preg-
nancy in weeks corrected for quality of life, that is,
quality-adjusted pregnancy weeks gained (QAPWs),
adverse drug reactions and pregnancy outcome (health
of the offspring). The QAPWs were calculated in the
following way: the achieved score on the Flanagan’s
scale was expressed as fraction of 1 (where 1 is
maximal score on the scale: 16 questions times
maximum grade 7, which equals 112 points), and this
number was multiplied with the prolongation in preg-
nancy in weeks.
The Costs
Only direct costs were taken into account in this
study. The costs of hospital days, services, materials,
and drugs used were collected from invoices sent to
RIHI by Clinical Center “Kragujevac” and outpatient
facilities in Kragujevac, for each patient studied. The
hospital day cost is a ﬂat-rate cost, which includes
only bed and food. The following services and mate-
rials were invoiced separately: physical examination,
intravenous, intramuscular or subcutaneous injection,
blood sample collection, electrocardiogram (ECG),
blood count, blood chemistry, etc. (services); and
infusion sets, needles, syringes, surgical gloves, cath-
eters, urine bags, dressings, etc. (materials). The
drugs used were also invoiced separately. The costs of
delivery and post-delivery care were not taken into
account, because they were not part of the hospital-
ization when tocolytic therapy was given. The costs
are expressed in Serbian ofﬁcial currency dinars
(CSD); the average exchange rate in January 2006
was 1 euro = 87 CSD.
Statistics
Both costs and effects are presented as mean values,
with standard deviations. Statistical signiﬁcance of dif-
ferences between the treatment groups was tested by
Student’s t-value for difference between small, inde-
pendent groups, or by chi-square contingency tables
(for comparing frequencies). The difference was con-
sidered signiﬁcant if probability of null hypothesis was
less than 0.05 (P < 0.05).
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Results
The mean length of pregnancy was similar in both
groups: 38.0  2.3 weeks in the ritodrine group, and
38.1  2.3 weeks in the fenoterol group (t = 0.259;
P > 0.05).
The prolongation of pregnancy was longer in the
fenoterol group (12.7  8.4 weeks) than in the rito-
drine group (11.6  7.1 weeks); however, this differ-
ence was not signiﬁcant (t = 1.058; P > 0.05).
The score on modiﬁed Flanagan’s quality-of-life
scale for chronic diseases, measured after discharge
from the hospital, was signiﬁcantly higher (t = 2.714;
P < 0.01) in the fenoterol group (88.4  0.8) than in
the ritodrine group (84.5  0.9).
There were more QAPWs with fenoterol
(10.0  6.6) than with ritodrine (8.6  5.3), but this
difference was not signiﬁcant (t = 1.621; P > 0.05).
In each of the groups there were two late abortions.
In the ritodrine group there were 94 newborns, and 23
(25%) of them were preterm; in the fenoterol group
there were 121 newborns, and 27 (22%) of them were
preterm. This difference was not signiﬁcant (chi-
square = 0.142; P > 0.05).
The adverse drug reactions with their frequencies in
both groups are shown in Table 1.
The mean duration of hospitalization was shorter in
the fenoterol group (11.9  8.8 days) than in ritodrine
group (14.9  11.3 days); the difference was signiﬁ-
cant (t = 2.041; P < 0.05).
The total treatment costs per patient were signiﬁ-
cantly less (t = 3.235; P < 0.005) in the fenoterol group
(15,338.00  10,930.27 CSD) than in the ritodrine
group (22,033.36  16,603.84 CSD). The structure of
the costs is shown in Table 2.
The total treatment costs per patient excluding oral
tocolytic therapy were signiﬁcantly less (t = 2.469;
P < 0.05) in the fenoterol group (14,389.31 
10,375.45 CSD) than in the ritodrine group (18,823.41
 13,944.52 CSD).
Table 1 The adverse reactions to tocolytics and their frequencies
Adverse drug reactions









Tachycardia 57 67.06 82 71.30
Palpitations 36 42.35 61 53.04
Tremor 73 85.88 97 84.35
Nausea 35 41.18 54 46.96
Vomiting 4 4.70 14 12.17
Facial ﬂushing 17 20.00 28 24.35
Headache 40 47.06 52 45.22
Irritability 13 15.29 22 19.13
Nervousness 27 31.76 52 45.22
Chest tightness 15 17.65 18 15.65
Vertigo 21 24.70 37 32.17
Diarrhea 1 1.18 3 2.61
Muscular weakness 57 67.06 80 69.56
Sweating 7 8.23 6 5.22
Redness of the palms 5 5.88 6 5.22
Constipation 0 0 2 1.74
Feeling of warmth 1 1.18 1 0.87
Fatigue 1 1.18 0 0
Tinnitus 0 0 1 0.87
Dyspnea 0 0 3 2.61
Pyrrosis 0 0 1 0.87
Feeling energetic 0 0 1 0.87
No adverse drug reactions at all 1 1.18 3 2.61
No signiﬁcant differences in frequencies were found.
Table 2 Structure of the treatment costs per patient.The mean cost values in CSD for both groups, with standard deviations, are
shown
Type of the costs Ritodrine group Fenoterol group
Total tocolytic acquisition costs* 5,170.94 4,756.15 1,936.43 1,535.60
Intravenous tocolytic acquisition costs† 1,961.29 1,952.34 987.73 942.46
Costs of services, materials, and other drugs‡ 5,760.47 4,735.18 4,558.52 3,865.31
Hospitalization costs§ 11,107.76 8,413.81 8,959.73 7,054.10
Total costs 22,033.36 16,603.84 15,338.00 10,930.27
*Signiﬁcant difference between the treatment groups (t = 6.041; P < 0.001).
†Signiﬁcant difference between the treatment groups (t = 4.2280; P < 0.05).
‡The difference between the treatment groups is not signiﬁcant (t = 1.916; P > 0.05).
§The difference between the treatment groups is not signiﬁcant (t = 1.909; P > 0.05).
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The treatment with fenoterol was more cost-
effective than the treatment with ritodrine, when the
costs of oral tocolytic therapy were included; however,
this difference was not statistically signiﬁcant. The cost
of treatment per gained week of pregnancy prolonga-
tion was 3345.51  7668.04 CSD in the fenoterol
group, and 4181.96  12,069.83 CSD in the ritodrine
group; the difference was not signiﬁcant (t = 0.561;
P > 0.05). The cost of treatment per gained QAPW
was 4256.24  9700.00 CSD in the fenoterol group,
and 5372.36  14,926.63 CSD in the ritodrine group;
the difference was not signiﬁcant (t = 0.602; P > 0.05).
The treatment with fenoterol was also more cost-
effective than the treatment with ritodrine, when the
costs of oral tocolytic therapy were excluded; however,
this difference was not statistically signiﬁcant. The cost
of treatment per gained week of pregnancy prolonga-
tion was 3188.12  7507.38 CSD in the fenoterol
group, and 3574.22  10,449.64 CSD in the ritodrine
group; the difference was not signiﬁcant (t = 0.289;
P > 0.05). The cost of treatment per gained QAPW
was 4554.49  11,499.05 CSD in the fenoterol group,
and 4965.79  12,984.92 CSD in the ritodrine group;
the difference was not signiﬁcant (t = 0.232; P > 0.05).
Discussion
Although a number of clinical trials have shown that
administration of b-mimetic agents is hardly more
effective than placebo in stopping preterm labor, these
agents are widely used, not only for short-term, intra-
venous tocolysis, but also for oral maintenance
therapy [15,16]. Signiﬁcant resources are spent on
b-mimetic tocolytics, and it is difﬁcult to persuade
patients and health practitioners that stopping a toco-
lytic will not provoke uterine contractions [16].
A therapeutic equivalence of b-mimetic agents has
been shown in several studies [17,18], suggesting the
acquisition cost of the drug is the most important
determinant of cost-effectiveness. In our study, fenot-
erol was as effective tocolytic as ritodrine, and no
signiﬁcant difference between the treatment groups
was observed in terms of the prolongation of preg-
nancy and percentage of preterm newborns. Interest-
ingly, quality of life was higher in the fenoterol group
(according to the higher score on Flanagan’s scale),
although the incidence of annoying adverse drug reac-
tions was similar in both groups. On the other hand,
total costs of treatment per patient in fenoterol group
were signiﬁcantly lower (both when costs of oral toco-
lytic therapy were included and excluded), because of
major difference in b-mimetic agent acquisition cost.
Although hospitalization was signiﬁcantly shorter in
the fenoterol group, the difference in hospitalization
costs did not contribute signiﬁcantly to overall costs
difference. It is direct consequence of extremely low
cost of bed day (less than 900 CSD) [12], which is
controlled by RIHI, and supported by very low cost of
health worker’s labor (average monthly salary of a
nurse is 15,000–20,000 CSD, and that of a physician
25,000–30,000 CSD) [19].
The differences in treatment costs per patient,
however, did not translate into signiﬁcant differences
in cost-effectiveness ratios, because of wide distribu-
tion of individual costs and effects. Fenoterol treat-
ment still has a tendency to be more cost-effective
(especially when costs of oral tocolytic therapy are
included), but a larger study would be needed to prove
signiﬁcance of the difference. According to our results,
abandoning oral tocolytic therapy from routine prac-
tice could further decrease this difference.
Taking into account low costs of hospitalization
and human labor in Serbia and other low–middle-
income countries in the region, the best strategy of a
health insurance funds would be to ﬁnance a
b-mimetic tocolytic with the lowest acquisition costs.
The results of this study suggest that for fenoterol this
beneﬁt would be maintained, or increased, with the
expected rise in the cots of hospitalization and health
workers labor costs during the process of socioeco-
nomic transition from low–middle-income to middle-
income economies.
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